Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

1. Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies.Applied health economics and health policy · 2023
   Pooled it
2. Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review.Frontiers in pharmacology · 2023
   Pooled it
3. Cost-utility analysis of add-on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China.ESC heart failure · 2025
   Article
4. Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial.Cardiovascular drugs and therapy · 2025
   Article
5. Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2025
   Review
6. Time-varying cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors in Chinese patients with heart failure and reduced ejection fraction: A microsimulation of the real-world population.Frontiers in pharmacology · 2025
   Article
7. Cost-Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
   Article
8. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.ESC heart failure · 2024
   Article
9. Influenza vaccination for heart failure patients: a cost-effectiveness analysis from the perspective of Chinese healthcare system.Frontiers in public health · 2024
   Article
10. Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.PloS one · 2024
    Article
11. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients.Diabetology & metabolic syndrome · 2023
    Article
12. Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.ESC heart failure · 2023
    Article
13. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.Frontiers in pharmacology · 2023
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as